세계의 심근경색 시장 보고서(2025년)
Myocardial Infarction Global Market Report 2025
상품코드 : 1824417
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,493,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,386,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,279,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

심근경색 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.4%로 성장할 전망이며, 29억 2,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 심혈관 건강에 대한 세계적인 노력, 재관류 요법에 대한 접근 확대, 심혈관 질환에 대한 RNA 치료제, 환자 중심 케어 모델, 미세 혈관 기능 장애에 대한 관심, 바이오 일렉트로닉스 의료에 기인합니다. 예측 기간 주요 동향으로는 심혈관 영상의 진보, 심장 수술 기술 진보, 원격 의료 진보, 진단에 있어서 인공지능의 통합, 리스크 예측을 위한 디지털 바이오마커의 혁신, 헬스케어 데이터 보안을 위한 블록 체인, AI 주도의 창약, 심장 재활 기술의 혁신 등이 있습니다.

향후 5년간의 성장률 7.4%라고 하는 예측은 전회 예측으로부터 0.1%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 관세 장벽은 아일랜드와 싱가포르에서 조달하는 약제 용출 스텐트와 고감도 트로포닌 측정기의 비용을 상승시키고, 구명 치료를 늦추거나 순환기과의 비용을 상승시킴으로써 미국의 응급 의료 시스템을 저해할 것으로 예측됩니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 그 영향이 더욱 광범위해질 것으로 보입니다.

심근 경색 시장의 성장이 기대되는 것은 흡연자 증가입니다. 담배, 시가, 파이프 등 흡연을 하는 사람은 담배 연기에 함유된 화학물질에 노출됩니다. 이 물질은 정맥과 동맥의 혈액을 진하게 하거나 응고시킬 수 있으며 심근경색을 일으키는 폐색으로 이어질 수 있습니다. 2023년 9월에 영국 국가 통계국이 발표한 데이터에 따르면 영국 인구 중 25-34세의 흡연자 비율이 가장 높았으며, 2022년에는 16.3%, 약 140만 명에 달한 것으로 나타났습니다. 이는 같은 연령층의 흡연율이 15.8%, 약 130만 명이었던 전년보다 증가했습니다. 그 결과, 흡연자 수 증가가 심근경색 시장의 성장을 가속하는 중요한 요인이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Myocardial infarction, commonly known as a heart attack, poses a severe health risk, occurring when the blood flow to a segment of the heart muscle is obstructed, leading to tissue damage or death. This critical condition is often instigated by elevated levels of low-density lipoprotein, hypertension, and tobacco use.

Within the realm of myocardial infarction treatment, various drug classes play pivotal roles in managing and mitigating the condition's impact. These encompass antiplatelet agents, glycoprotein IIB/IIIA inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers, analgesics, and thrombolytics. Antiplatelet agents specifically target the prevention of blood clot formation by inhibiting platelet aggregation. Available in both oral and injectable formulations, these agents are accessible through a diverse range of distribution channels, including hospital pharmacies, retail pharmacies, and online platforms.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The myocardial infarction market research report is one of a series of new reports from The Business Research Company that provides myocardial infarction market statistics, including myocardial infarction industry global market size, regional shares, competitors with a myocardial infarction market share, detailed myocardial infarction market segments, market trends and opportunities, and any further data you may need to thrive in the myocardial infarction industry. This myocardial infarction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myocardial infarction market size has grown strongly in recent years. It will grow from $2.05 billion in 2024 to $2.19 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to the introduction of beta-blockers, the establishment of chest pain centers, thrombolytic therapies, personalized medicine approaches, and wearable cardiovascular devices.

The myocardial infarction market size is expected to see strong growth in the next few years. It will grow to $2.92 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to global health initiatives for cardiovascular health, expanded access to reperfusion therapies, RNA therapeutics for cardiovascular diseases, patient-centered care models, focus on microvascular dysfunction, and bioelectronic medicine. Major trends in the forecast period include advancements in cardiovascular imaging, advancements in cardiac surgery techniques, advancements in telemedicine, integration of artificial intelligence in diagnosis, innovation of digital biomarkers for risk prediction, blockchain for healthcare data security, ai-driven drug discovery, and innovations in cardiac rehabilitation technologies.

The forecast of 7.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. emergency care system by increasing the cost of drug-eluting stents and high-sensitivity troponin assays sourced from Ireland and Singapore, thereby delaying life-saving interventions and elevating cardiology department costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth of the myocardial infarction market is expected to be driven by an increasing number of smokers. Individuals who engage in smoking, whether through cigarettes, cigars, or pipes, expose themselves to chemicals present in tobacco smoke. These substances have the potential to thicken and clot the blood in veins and arteries, leading to blockages that can result in myocardial infarction. A notable example is the data from the UK-based Office for National Statistics in September 2023, revealing that the segment of the UK population aged 25 to 34 years had the highest percentage of current smokers, accounting for 16.3% or approximately 1.4 million individuals in 2022. This marked an increase from the previous year, when the same age group had a smoking prevalence of 15.8%, encompassing around 1.3 million people. Consequently, the growing number of smokers is a significant factor propelling the growth of the myocardial infarction market.

The increasing prevalence of cardiovascular diseases is anticipated to drive the growth of the myocardial infarction market in the future. Cardiovascular diseases encompass a range of disorders that affect the heart and blood vessels. Drug classes for myocardial infarction are used to manage and treat these conditions, particularly in the aftermath of heart attacks. For example, in September 2024, data published by the British Heart Foundation, a UK-based cardiovascular research charity, indicated that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, comprising about 4 million males and 3.6 million females. These conditions account for around 27% of all deaths in the UK, resulting in over 170,000 fatalities annually, or roughly 480 deaths each day, which translates to one death every three minutes. Thus, the rising incidence of cardiovascular diseases is fueling the growth of the myocardial infarction market.

Major companies in the myocardial infarction market are focused on developing novel drugs, such as anti-inflammatory drugs, for targeted cardiovascular inflammation treatment and to gain a competitive edge in the market. Anti-inflammatory drugs are medications that reduce inflammation, alleviating pain and swelling by targeting the body's immune response. For instance, in June 2023, Agepha Pharma, a Slovakia-based manufacturer of medical products, received FDA approval for its developed drug, Lodoco (colchicine), the first anti-inflammatory drug to target the underlying cause of atherosclerotic cardiovascular disease. Lodoco aims to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients. It can be used alone or with cholesterol-lowering medications. Lodoco, a reformulated low-dose colchicine, demonstrated a 31% reduction in the overall risk of cardiovascular death, myocardial infarction, stroke, or coronary revascularization in a clinical trial.

Major companies in the myocardial infarction market are focused on developing advanced devices that utilize technology, such as SmartAssist dual-sensor technology, to address acute right heart failure and to maximize their profits in the market. SmartAssist dual-sensor technology refers to a system equipped with two sensors designed to gather and monitor advanced metrics in a medical device. For instance, in October 2022, Abiomed, a US-based provider of medical technology, received FDA approval for its Impella RP Flex with SmartAssist. It is implanted via the internal jugular vein; it allows patient mobility and features dual-sensor technology for optimal patient management and weaning. The Impella RP platform includes percutaneous right heart mechanical circulatory support technologies designed for native heart recovery. Impella RP with SmartAssist has received approval from the U.S. FDA for the treatment of right heart failure or decompensation after procedures including left ventricular assist device implantation, myocardial infarction, and heart transplant.

In December 2022, Johnson & Johnson, a leading US-based healthcare products conglomerate, finalized the acquisition of Abiomed for a notable sum of $16.6 billion. This strategic acquisition positions Johnson & Johnson MedTech to integrate heart recovery solutions from Abiomed into its existing Biosense Webster electrophysiology division. By doing so, Johnson & Johnson aims to augment its offerings in the rapidly growing cardiovascular sector. Abiomed, renowned for its pioneering clinical research, specializes in the treatment of acute myocardial infarction, further enriching Johnson & Johnson's comprehensive cardiovascular solutions portfolio.

Major companies operating in the myocardial infarction market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Boehringer Ingelheim GmbH, Merck KGaA, Daiichi Sankyo Co. Ltd., Apotex Inc., Siemens Healthcare Diagnostics Limited, Annexin Pharmaceuticals AB, Heartseed Inc., Par Pharmaceutical Companies Inc., Tenaya Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Acesion Pharma ApS, Applied Therapeutics Inc., Athersys Inc., Cardurion Pharmaceuticals Inc., Verve Therapeutics Inc., Serca Pharmaceuticals AS

North America was the largest region in the myocardial infarction market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the myocardial infarction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myocardial infarction market consists of sales of heparin, bivalirudin, and enoxaparin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myocardial Infarction Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myocardial infarction market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for myocardial infarction ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The myocardial infarction market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Myocardial Infarction Market Characteristics

3. Myocardial Infarction Market Trends And Strategies

4. Myocardial Infarction Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Myocardial Infarction Growth Analysis And Strategic Analysis Framework

6. Myocardial Infarction Market Segmentation

7. Myocardial Infarction Market Regional And Country Analysis

8. Asia-Pacific Myocardial Infarction Market

9. China Myocardial Infarction Market

10. India Myocardial Infarction Market

11. Japan Myocardial Infarction Market

12. Australia Myocardial Infarction Market

13. Indonesia Myocardial Infarction Market

14. South Korea Myocardial Infarction Market

15. Western Europe Myocardial Infarction Market

16. UK Myocardial Infarction Market

17. Germany Myocardial Infarction Market

18. France Myocardial Infarction Market

19. Italy Myocardial Infarction Market

20. Spain Myocardial Infarction Market

21. Eastern Europe Myocardial Infarction Market

22. Russia Myocardial Infarction Market

23. North America Myocardial Infarction Market

24. USA Myocardial Infarction Market

25. Canada Myocardial Infarction Market

26. South America Myocardial Infarction Market

27. Brazil Myocardial Infarction Market

28. Middle East Myocardial Infarction Market

29. Africa Myocardial Infarction Market

30. Myocardial Infarction Market Competitive Landscape And Company Profiles

31. Myocardial Infarction Market Other Major And Innovative Companies

32. Global Myocardial Infarction Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myocardial Infarction Market

34. Recent Developments In The Myocardial Infarction Market

35. Myocardial Infarction Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기